Skip to content
The Kids Research Institute Australia logo
Donate

Search

Showing results for "8"

Our Locations

At The Kids Research Institute Australia, we have a dedicated and diverse team of over 1,000 staff, students and honorary researchers.

Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination

In Australia, following the introduction of serogroup C meningococcal (MenC) conjugate vaccine for toddlers and catch-up immunization through adolescence,...

Pregnancy, Babies & Children's Expo PERTH

Discover what's best for you, your pregnancy, baby or child at the Pregnancy Babies & Children's Expo - the must see parenting event of the year!

Person Reported Outcomes

The PCH Diabetes Clinical team will again be collecting T1DAL surveys between June and July 2024, followed by PAID between November 2024 and January 2025.

Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers

One dose of MenACWY-TT boosts protection against MenC in primed children, is safe and extends protection against MenA, MenW and MenY

The dangers of melanoma

Head of Cancer Immunotherapy Research at the The Kids Cancer Centre, Dr Jason Waithman, says Australia has one of the highest rates of skin cancer in the world.

Register your interest for CliniSibs

We are currently taking expressions of interest for CliniSibs in 2024.

Putting a price on nurturing care

At the halfway mark for implementation of the Sustainable Development Agenda, progress towards achieving targets centred on child health and development has decelerated, impeding the survival and potential of many children. The Lancet Series on optimising child and adolescent health and development called for renewed efforts to nurture the health and development of all children.

Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin-Piperaquine

Mass drug administration (MDA) with monthly dihydroartemisinin-piperaquine (DHA-PQP) appears useful in malaria control and elimination strategies. Determining the relationship between consecutive piperaquine phosphate (PQP) exposure and its impact on QT interval prolongation is a key safety consideration for MDA campaigns.